Benzinga | May 5, 2021 09:27AM EDT

Hoth Therapeutics Says Co, Virginia Commonwealth University Expand Research Agreement For COVID-19 Therapeutic

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

Based on positive preclinical results generated by Dr. Michael Peters against COVID-19 using live virus inhibition assays, Hoth has amended its original scientific agreement with VCU and has agreed to further develop Dr. Peters's novel peptide COVID-19 Therapeutic, HT-002. Hoth Therapeutics has an exclusive license to this novel peptide COVID-19 therapeutic.



The expanded research agreement will focus on investigating the potential of HT-002 to inhibit SARS-CoV-2 virus variants. This work will be informed by the molecular modeling of SARS-CoV-2 spike peptide sequences from strain variants, reported in the preprint publication in bioRxiv earlier this year.